Prima Biomed reports upbeat interim data

Prima BioMed Ltd. (Nasdaq: PBMD) reported upbeat interim data for its TACTI-mel clinical program for IMP321 in unresectable or metastatic melanoma patients lifting the stock price 17 cents to close at $2.50.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.